MicroRNA in colorectal cancer: From benchtop to bedside

140Citations
Citations of this article
117Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Colon carcinogenesis represents a stepwise progression from benign polyps to invasive adenocarcinomas and distant metastasis. It is believed that these pathologic changes are contributed by aberrant activation or inactivation of protein-coding proto-onco genes and tumor suppressor genes. However, recent discoveries in microRNA (miRNA) research have reshaped our understanding of the role of non-protein-coding genes in carcinogenesis. In this regard, a remarkable number of miRNAs exhibit differential expression in colon cancer tissues. These miRNAs alter cell proliferation, apoptosis and metastasis through their interactions with intracellular signaling networks. From a clinical perspective, polymorphisms within miRNA-binding sites are associated with the risk for colon cancer, whereas miRNAs isolated from feces or blood may serve as biomarkers for early diagnosis. Altered expression of miRNA or polymorphisms in miRNA-related genes have also been shown to correlate with patient survival or treatment outcome. With further insights into miRNA dysregulation in colon cancer and the advancement of RNA delivery technology, it is anticipated that novel miRNA-based therapeutics will emerge. © The Author 2010. Published by Oxford University Press. All rights reserved.

Cite

CITATION STYLE

APA

Wu, W. K. K., Law, P. T. Y., Lee, C. W., Cho, C. H., Fan, D., Wu, K., … Sung, J. J. Y. (2011, March 1). MicroRNA in colorectal cancer: From benchtop to bedside. Carcinogenesis. Oxford University Press. https://doi.org/10.1093/carcin/bgq243

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free